Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
´ëÇÑ¿Ü°úÇÐȸÁö 2013³â 85±Ç 1È£ p.7 ~ p.14
È«¿ì¼º(Hong Woo-Sung) - Ajou University School of Medicine Department of Surgery
ÀüÀÚ¿µ(Jeon Ja-Young) - Ajou University School of Medicine Department of Hematology-Oncology
°¼®À±(Kang Seok-Yun) - Ajou University School of Medicine Department of Hematology-Oncology
Á¤¿ë½Ä(Jung Yong-Sik) - Ajou University School of Medicine Department of Surgery
±èÁö¿µ(Kim Ji-Young) - Ajou University School of Medicine Department of Surgery
¾È¹Ì¼±(Ahn Mi-Sun) - Ajou University School of Medicine Department of Hematology-Oncology
°µÎ°æ(Kang Doo-Kyoung) - Ajou University School of Medicine Department of Radiology
±èÅÂÈñ(Kim Tae-Hee) - Ajou University School of Medicine Department of Radiology
ÀÓÇöÀÌ(Yim Hyun-Ee) - Ajou University School of Medicine Department of Pathology
¾È¿µ½Ç(An Young-Sil) - Ajou University School of Medicine Department of Nuclear Medicine
¹Ú·¡¿õ(Park Rae-Woong) - Ajou University School of Medicine Department of Biomedical Informatics
±è±¸»ó(Kim Ku-Sang) - Ajou University School of Medicine Department of Surgery
Abstract
Purpose : Neoadjuvant chemotherapy is the standard treatment for patients with locally advanced breast cancer and is increasingly considered for patients with operable disease. Recently, as many clinical trials have demonstrated favorable outcomes of anthracycline-taxane based regimen, this approach has been widely used in the neoadjuvant setting. Methods : We compared women who received adriamycine and docetaxel (AD) with adriamycin, cyclophosphamide followed by paclitaxel (AC-T) as neoadjuvant chemotherapy. The AD group was scheduled for six cycles of AD (50 mg/m2 and 75 mg/m2, respectively) at a 3-week interval. The AC-T group was scheduled for four cycles of adriamycin and cyclophosphamide (50 mg/m2 and 500 mg/m2, respectively) followed by four cycles of paclitaxel (175 mg/m2) at a 3-week interval. Results : The responses of chemotherapy were equivalent (overall response rate [AD, 75.7% vs. AC-T, 80.9%; P = 0.566], pathologic complete response [pCR] rate [breast and axilla: AD, 10.8% vs. AC-T, 12.8%; P = 1.000; breast only: AD, 18.9% vs. AC-T, 14.9%, P = 0.623], breast conserving surgery rate [P = 0.487], and breast conserving surgery conversion rate [P = 0.562]). The pCR rate in the breast was higher in the human epidermal growth factor receptor 2 (HER2) positive cases (HER2 positive 33.3% vs. negative 10%, P = 0.002). Although nonhematologic toxicities were comparable, hematologic toxicities were more severe in the AD group. Most women in the AD group suffered from grade 3/4 neutropenia (P < 0.001) and neutropenic fever (P < 0.001). Conclusion : Tumor responses were not different in various variables between the two groups. However, AC-T was a more tolerable regimen than AD in patients with breast cancer receiving neoadjuvant chemotherapy.
Å°¿öµå
Breast neoplasms, Neoadjuvant therapy
KMID :
0371320130850010007
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Most women in the AD group suffered from grade 3/4 neutropenia (P < 0.001) and neutropenic fever (P < 0.001). Tumor responses were not different in various variables between the two groups. However, AC-T was a more tolerable regimen than AD in patients with breast cancer receiving neoadjuvant chemotherapy.